Shivalik Rasayan Board Approves Equity Share Issue of 93 Million Rupees

NEW DELHI — Shivalik Rasayan Limited's Board of Directors has formally approved a proposal to issue fresh equity shares for an aggregate value of up to ₹93 million (₹9.3 crore).

The board's approval was confirmed through regulatory disclosures filed with domestic stock exchanges. The decision to raise fresh equity capital is aimed at bolstering the company's balance sheet, supporting ongoing capital expenditure projects, and meeting general corporate and working capital demands.

This equity allotment aligns with Shivalik Rasayan’s strategic focus on scaling up its agrochemical production capabilities alongside its expanding active pharmaceutical ingredients (API) manufacturing footprint in Dahej, Gujarat.

Equity Structure and Capital Deployment

The issuance of equity shares worth ₹93 million will be executed in accordance with guidelines mandated by the Securities and Exchange Board of India (SEBI) and applicable provisions of the Companies Act.

Key details regarding the capital transaction include:

• Total Transaction Value: Up to ₹93 million (₹9.3 crore).

• Instrument Type: Fresh Equity Shares.

• Regulatory Oversight: Subject to statutory approvals and shareholder consent where applicable.

• Deployment Objectives: Strengthening working capital reserves, funding R&D activities, and enhancing operational cash flows across manufacturing units.

The equity infusion provides non-dilutive debt relief, allowing Shivalik Rasayan to expand operational cash reserves without increasing interest obligations.

Operational Background and Market Positioning

Founded as an agrochemical manufacturer specializing in organophosphate insecticides like Dimethoate Technical and Malathion Technical, Shivalik Rasayan has significantly diversified its operational base.

Through strategic investments and facility commissioning at Dahej, the company has transitioned into high-value specialized agrochemicals and generic API production. Additionally, Shivalik Rasayan holds a major strategic stake in pharmaceutical firm Medicamen Biotech Limited, providing a dual footprint across agricultural chemicals and human health formulations.

The added liquidity from the ₹93 million equity issuance will allow the company to maintain consistent raw material sourcing, optimize supply chain timelines, and scale output across its specialized technical blocks.

Official Sources Statement

In official regulatory filings submitted to stock exchanges, Shivalik Rasayan Limited detailed the corporate authorization:

"According to officials and regulatory filings submitted to the stock exchanges, the Board of Directors of Shivalik Rasayan Limited has approved the issuance of equity shares aggregating up to ₹93 million, subject to necessary regulatory and shareholder approvals."

Company officials noted that the capital allocation will be executed through established market mechanisms compliant with SEBI regulations.

Why It Matters

For investors, industry watchers, and commercial partners, Shivalik Rasayan's equity issuance holds key practical implications:

1. Balance Sheet Health: Raising capital via equity prevents additional leverage, maintaining a manageable debt-to-equity ratio.

2. Capacity Utilization: Direct cash injection supports continuous operations at newly commissioned specialized chemical plants.

3. Market Confidence: Equity backing underscores ongoing promoter and institutional trust in the company's long-term growth roadmap.

Key Facts at a Glance

• Company: Shivalik Rasayan Limited (NSE: SHIVALIK | BSE: 539148)

• Transaction Value: Equity shares worth up to ₹93 million (₹9.3 crore)

• Corporate Head Office: New Delhi, India

• Key Segments: Agrochemicals, Insecticides, Active Pharmaceutical Ingredients (APIs)

• Governing Regulations: SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations

Frequently Asked Questions (FAQs)

What is Shivalik Rasayan Limited's primary business activity?

Shivalik Rasayan Limited is an Indian chemical manufacturing company that produces organophosphate agrochemicals (such as Malathion and Dimethoate) as well as specialized active pharmaceutical ingredients (APIs).

What was approved by the Board of Directors?

The Board of Directors approved the issuance of fresh equity shares worth up to ₹93 million to raise long-term capital.

Where are Shivalik Rasayan's equity shares traded?

Shivalik Rasayan’s equity shares are listed and traded on both the National Stock Exchange of India (NSE) under the ticker SHIVALIK and the BSE Limited under the security code 539148.

How will the proceeds from the equity issuance be used?

The proceeds are designated primarily for strengthening working capital reserves, supporting business growth, and funding operational needs across the company's production facilities.

Source: Official regulatory disclosures filed with BSE India, National Stock Exchange of India, and corporate announcements from Shivalik Rasayan Limited.